Indian stocks: Visit www.stage2stocks.com →

Niagen Bioscience, Inc.

Stage 4 · Declining · week 50

As of Oct 22, 2026, Niagen Bioscience is in Stage 4, the downtrend phase, now in week 50 (since Oct 29, 2025). It closed at $2.52, 66.8% below its 52-week high and below its 200-day average, which is falling.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. More about the company

$2.52
+2.02% today
$199M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NAGE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S2 15w
S2 23w
S2 22w
S4 51w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S4 16w → S1 9w → S2 15w → S3 10w → S2 23w → S3 5w → S2 22w → S3 11w → S4 51w current
Total tracked: 166 weeks across 10 stage runs.

NAGE among Packaged Foods48th of 65 by relative strength

All 65 →
Stocks in Packaged Foods ranked by relative strength, with stage and one-month change
#StockStageRS1M
1DARStage 2 · wk 1093−9.3%
2WESTStage 2 · wk 493+19.9%
3HLFStage 1 · wk 289+14.9%
4SENEBStage 2 · wk 3487−4.8%
5CENTStage 3 · wk 684+14.3%
6SENEAStage 2 · wk 3881−8.3%
7CENTAStage 3 · wk 681+13.6%
8SJMStage 2 · wk 1778+9.0%
…48NAGEStage 4 · wk 5016−16.0%
vs 52W High
-66.8%
$2.47 lo$7.60 hi
66.8% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 50
1w13w26w
Week 50, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-37.6%
200 DMA: $4.04 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.05x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-16.0%
3M
-21.5%
6M
-46.7%
YTD
-59.7%
1Y
-66.4%
Scan Membership
Breakout Watch
Latest: 2025-03-13
10 appearances in last 60 days. First seen: 2019-04-12.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 50 · Vol 1.05x
2026-10-21S4
Wk 50 · Vol 1.22x
2026-10-20S4
Wk 49 · Vol 1.07x
2026-10-19S4
Wk 49 · Vol 1.04x
2026-10-16S4
Wk 49 · Vol 1.13x
2026-10-15S4
Wk 49 · Vol 0.85x
2026-10-14S4
Wk 49 · Vol 0.98x
2026-10-13S4
Wk 48 · Vol 1.17x
2026-10-12S4
Wk 48 · Vol 0.74x
2026-10-09S4
Wk 48 · Vol 0.48x
2026-10-08S4
Wk 48 · Vol 1.14x
2026-10-07S4
Wk 48 · Vol 0.64x
Moving averages & range
50 DMA
$2.93
200 DMA
$4.04
52W High
$7.60
52W Low
$2.47
5D Low
$2.47
Resistance levels (recent highs)
20d High
$3.05
60d High
$3.53
120d High
$4.97
250d High
$7.60
Next resistance
+21.0%
to 20d High
P/E (TTM)
13.3
Forward -42.0
Earnings Growth (YoY)
-75.0%
Revenue -4.3%
ROE
+21.8%
Profit margin +12.4%
Dividend Yield
0.00%
P/B 2.4

Niagen Bioscience: quick answers

What stage is Niagen Bioscience in?

As of Oct 22, 2026, Niagen Bioscience (NAGE) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 29, 2025 and is in week 50. What the four stages mean

Is Niagen Bioscience in an uptrend?

No. Niagen Bioscience is in a Stage 4 downtrend. It trades 37.6% below its 200-day average, which is falling.

How far is Niagen Bioscience from its 52-week high?

Niagen Bioscience closed at $2.52 on Oct 22, 2026, 66.8% below its 52-week high of $7.60. Its 52-week low is $2.47.

How has Niagen Bioscience performed over the past year?

As of Oct 22, 2026, Niagen Bioscience is down 66.4% over the past year and down 59.7% so far in 2026.

Which sector and industry is Niagen Bioscience in?

Niagen Bioscience is in the Packaged Foods industry, part of the Consumer Staples sector.

About this companyConsumer Staples· Packaged Foods

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.